Kunming Longjin Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Kunming Longjin Pharmaceutical's earnings have been declining at an average annual rate of -47.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 17.7% per year.
Key information
-47.2%
Earnings growth rate
-47.1%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -17.7% |
Return on equity | -13.7% |
Net Margin | -72.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
What Kunming Longjin Pharmaceutical Co., Ltd.'s (SZSE:002750) 38% Share Price Gain Is Not Telling You
Aug 14Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) May Have Run Too Fast Too Soon With Recent 40% Price Plummet
Jun 30Risks Still Elevated At These Prices As Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) Shares Dive 26%
Apr 26We're Not Very Worried About Kunming Longjin Pharmaceutical's (SZSE:002750) Cash Burn Rate
Apr 17Revenues Not Telling The Story For Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) After Shares Rise 29%
Mar 08Revenue & Expenses Breakdown
How Kunming Longjin Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 82 | -59 | 90 | 19 |
31 Mar 24 | 91 | -67 | 98 | 20 |
31 Dec 23 | 87 | -71 | 95 | 22 |
30 Sep 23 | 91 | -79 | 98 | 23 |
30 Jun 23 | 88 | -69 | 92 | 23 |
31 Mar 23 | 97 | -65 | 98 | 25 |
01 Jan 23 | 123 | -56 | 110 | 25 |
30 Sep 22 | 211 | -7 | 133 | 23 |
30 Jun 22 | 383 | -4 | 162 | 23 |
31 Mar 22 | 544 | 1 | 191 | 18 |
01 Jan 22 | 703 | 3 | 208 | 20 |
30 Sep 21 | 683 | 16 | 211 | 15 |
30 Jun 21 | 551 | 18 | 210 | 18 |
31 Mar 21 | 419 | 19 | 200 | 19 |
31 Dec 20 | 254 | 12 | 186 | 20 |
30 Sep 20 | 251 | -22 | 186 | 23 |
30 Jun 20 | 245 | -26 | 184 | 20 |
31 Mar 20 | 251 | -33 | 194 | 23 |
31 Dec 19 | 275 | -23 | 209 | 21 |
30 Sep 19 | 273 | 1 | 222 | 24 |
30 Jun 19 | 299 | 4 | 241 | 29 |
31 Mar 19 | 318 | 12 | 251 | 33 |
31 Dec 18 | 336 | 14 | 267 | 32 |
30 Sep 18 | 341 | 19 | 272 | 28 |
30 Jun 18 | 339 | 23 | 253 | 41 |
31 Mar 18 | 328 | 28 | 240 | 29 |
31 Dec 17 | 304 | 35 | 211 | 27 |
30 Sep 17 | 287 | 48 | 185 | 22 |
30 Jun 17 | 262 | 81 | 169 | 0 |
31 Mar 17 | 238 | 89 | 131 | 0 |
31 Dec 16 | 224 | 91 | 108 | 0 |
30 Sep 16 | 196 | 91 | 80 | 0 |
30 Jun 16 | 182 | 67 | 58 | 0 |
31 Mar 16 | 179 | 63 | 55 | 0 |
31 Dec 15 | 181 | 62 | 53 | 0 |
30 Sep 15 | 194 | 64 | 50 | 0 |
30 Jun 15 | 194 | 66 | 51 | 0 |
31 Mar 15 | 195 | 67 | 53 | 0 |
31 Dec 14 | 187 | 64 | 51 | 0 |
31 Dec 13 | 179 | 75 | 44 | 0 |
Quality Earnings: 002750 is currently unprofitable.
Growing Profit Margin: 002750 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002750 is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
Accelerating Growth: Unable to compare 002750's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002750 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 002750 has a negative Return on Equity (-13.7%), as it is currently unprofitable.